1 Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury Simone Di Giovanni*, Vilen Movsesyan*, Farid Ahmed*, Ibolja Cernak*, Sergio Schinelli, Bogdan Stoica*, and Alan I. Faden* *Department of Neuroscience, Georgetown University School of Medicine, 3900 Reservoir Road NW, Washington, DC 20057; and Dipartimento di Farmacologia Sperimentale ed Applicata, Facoltà di Farmacia, Università di Pavia, Viale Taramelli 14, Pavia, Italy Edited by L. L. Iversen, University of Oxford, Oxford, United Kingdom, and approved April 14, 2005 (received for review February 9, 2005) Traumatic brain injury (TBI) causes neuronal apoptosis, inflammation, and reactive astrogliosis, which contribute to secondary tissue loss, impaired regeneration, and associated functional disabilities. Here, we show that up-regulation of cell cycle components is associated with caspase-mediated neuronal apoptosis and glial proliferation after TBI in rats. In primary neuronal and astrocyte cultures, cell cycle inhibition (including the cyclin-dependent kinase inhibitors flavopiridol, roscovitine, and olomoucine) reduced upregulation of cell cycle proteins, limited neuronal cell death after etoposide-induced DNA damage, and attenuated astrocyte proliferation. After TBI in rats, flavopiridol reduced cyclin D1 expression in neurons and glia in ipsilateral cortex and hippocampus. Treatment also decreased neuronal cell death and lesion volume, reduced astroglial scar formation and microglial activation, and improved motor and cognitive recovery. The ability of cell cycle inhibition to decrease both neuronal cell death and reactive gliosis after experimental TBI suggests that this treatment approach may be useful clinically. flavopiridol glial scar neuron trauma Traumatic brain injury (TBI) induces secondary molecular changes that lead to neuronal death, microglial activation, inflammation, and reactive astrogliosis. Collectively, these alterations contribute to tissue loss, as well as to glial scar formation that may serve to impair recovery (1, 2). Neuronal apoptosis is an important mechanism of cell death in many models of acute and chronic neurodegeneration. Both caspase-dependent and independent apoptotic pathways have been identified in CNS trauma, although the former has received the most attention (1, 3 7). Other pathways also play a role in cell death after CNS injury, including activation of proteases (calpains and cathepsins) (8, 9), the mitogen-activated protein kinase (MAPK)-signaling cascade (10, 11), and cell cycle progression (12 14) among others. Cell cycle induction leading to apoptotic neuronal death has been described in vitro (15 20) and in vivo, including animal models of stroke, amyotrophic lateral sclerosis, and Alzheimer s disease (12, 21 25). Although aberrant cell cycle activation can lead to apoptosis in postmitotic cells, cell cycle transition can also induce proliferation in mitotic cells such as astrocytes and microglia after brain ischemia (26, 27). Activation of such cells is responsible for reactive gliosis, characterized by hyperplasia, hypertrophy, and increase in glial fibrillary acidic protein (GFAP) immunostaining. Reactive gliosis is observed after CNS injuries, including ischemia and trauma. Although microglia and astrocytes secrete important growth factors for neurons, their role after CNS injury seems detrimental for neuronal survival and regeneration (28 31). Using Affymetrix (Santa Clara, CA) microarrays, we found induction of genes signaling DNA damage and progression of cell cycle following fluid percussion (FP)-induced TBI. Protein expression for these genes was localized in neurons, particularly in those showing expression of caspase 3, as well as in proliferating astrocytes and microglia. In etoposide-treated neuronal cell cultures, cell cycle inhibitors reduced cell cycle protein expression, reduced caspase-mediated apoptosis, and impaired astrocyte proliferation after serum stimulation in culture. Following TBI, flavopiridol reduced neuronal apoptosis, reduced astroglial scar formation, decreased lesion volume, and significantly improved motor and cognitive performance. Materials and Methods Rat Lateral FP Trauma Model. Male Sprague Dawley rats ( g) were anesthetized with sodium pentobarbital (60 mg kg i.p.). Brain temperature was assessed through a thermister in the temporalis muscle, and body temperature was maintained at C. Trauma was induced as described (32). Sham rats (four rats at the 4-h time point and two rats per time point at 8, 24, and 72 h) were subjected to anesthesia and surgery but were not injured. Three unanesthetized, uninjured rats served as naive controls. Expression Profiling. Tissue from one rat was used for each expression-profiling experiment. Brain tissue was homogenized, RNA was extracted with TRIzol, and expression profiling was performed as described (32, 33) by using rat U34A high-density oligonucleotide microarrays (Affymetrix). Between two and four animals were studied per time point, at 0, 4, 24, and 72 h for each experimental group, including sham and injured. Microarray Quality Control and Data Analysis. Each microarray underwent a stringent quality control evaluation as described (32, 33). Such data analysis retained the probe sets with the most reliable and consistent performance between multiple measurements among arrays of the same experimental group. Experiment normalization and statistical analysis were performed by using GENE- SPRING 5.0 software (Silicon Genetics, Redwood, CA) as described (34). We selected for detailed functional analyses only those transcripts that showed a Welch ANOVA t test P value 0.05 and a fold change of at least 1.5 between sham and injured animals for each time point. Functional analysis used the GENESPRING gene ontology tool, DAVID, and GENEMAPP (34). Semiquantitative RT-PCR. One microgram of total RNA was used for cdna synthesis by using SuperScript reverse transcriptase and oligo(dt)-primer (Invitrogen). The amount of synthesized cdna was evaluated by PCR by using primers specific for ribosomal protein RPL19. PCRs were performed as described (32). This paper was submitted directly (Track II) to the PNAS office. Abbreviations: FP, fluid percussion; TBI, traumatic brain injury; GFAP, glial fibrillary acidic protein; GADD45, growth arrest and DNA damage inducible protein 45; CDK, cyclindependent kinase; PCNA, proliferating cell nuclear antigen; LDH, lactate dehydrogenase; i.c.v., intracerebroventricularly. S.D.G., V.M., and F.A. contributed equally to this work. To whom correspondence should be addressed by The National Academy of Sciences of the USA NEUROSCIENCE cgi doi pnas PNAS June 7, 2005 vol. 102 no
2 Immunoblotting. Proteins from both frozen rat spinal cord tissues and cultured rat cortical neurons and astrocytes were processed for immunoblotting by standard procedures (see Supporting Materials and Methods, which is published as supporting information on the PNAS web site). Immunocytochemistry. Immunocytochemistry from three injured and two sham animals was performed at 24 h, 72 h, and 28 days. Frozen 12- m cerebral cortex sections from three injured and two sham animals were incubated under the same coverslip and processed for immunocytochemistry following standard procedures (see Supporting Materials and Methods). Cell Culture. Rat primary cortical neurons. Cortical neuronal cultures were derived from rat embryonic cortices. Cortices from 15- to 16-day-old embryos were cleaned from their meninges and blood vessels, minced, and dissociated as described (9). More information is available in Supporting Materials and Methods. Rat primary astrocytes. Purified astrocyte cultures were prepared from 20-day-old Sprague Dawley rat embryos. Cortices were dissected and then mechanically dissociated as described (35). The cultures comprise 95% GFAP-positive cells (35). For detailed information, see Supporting Materials and Methods. MRI. At 21 days after injury, animals were examined by using a Bruker (Billerica, MA) 7.0-tesla spectrometer imager, as described (9). Lesion volumes were estimated from the summation of areas of hyperintensity in cerebrum multiplied by slice thickness by using Bruker PARAVISION 2.1 imaging software. Motor Function Assessment. Motor function was evaluated by using standardized motor scoring, i.e., composite neuroscore on days 1, 2, 3, 7, 14, 15, 16, and 17 posttrauma as described (36). Tests included the ability to maintain position on an inclined plane in two vertical and two horizontal positions, forelimb flexion, and forced lateral pulsion; composite neurological scores range from 0 to 35. Cognitive Function Assessment. Spatial learning was tested by using the Morris water maze, as described (36). A series of 16 training trials administered in blocks of 4 with an intertribal interval of 30 min were conducted on days 14 to 17 postinjury. To control for motor impairment, animals were tested to locate a visible platform atleast2hafterthelasttrainingtrial. Drugs. Flavopiridol was provided by the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Heath; roscovitine and olomoucine were purchased from Calbiochem; etoposide was obtained from Sigma. Results DNA Damage and Cell Cycle-Related Genes Are Induced After Brain Trauma. To investigate potential molecular factors involved in secondary injury after TBI, we used Affymetrix high-density oligonucleotide microarrays. We generated a list of significantly altered genes, including those profiles with at least 40% of present P calls, a fold change of 1.5, and a Welch ANOVA t test P value 0.05 between sham and injured samples for each time point (for complete gene list, see ref. 32). We found significantly increased expression for a number of DNA damage-related and cell cycle genes, including growth arrest and DNA damage inducible protein 45 (GADD45), c-myc, cyclin D1, cdk-4, E2F-5, and proliferating cell nuclear antigen (PCNA) between 4 and 72 h (Fig. 1 a and b). In contrast, cell cycle inhibitor genes were either unchanged (p21) or significantly down-regulated (p27) at the same time points (data not shown). To validate these expression-profiling data, we performed RT- PCR in parallel rat sham and injured samples (0, 4, 8, 24, and 72 h); these data confirmed microarray mrna expression changes for GADD45, c-myc, PCNA, and p27 (Fig. 1c). Immunoblotting was also performed to quantify protein expression in both sham and injured animals at representative time points after injury (24 and 72 h) (Fig. 1 d and e). Increased expression for GADD45, PCNA, and cyclin D1 and down-regulation for p27 were found in injured brains compared with shams (Fig. 1 d and e), which paralleled mrna expression changes. Cyclin-Dependent Kinase (CDK) Inhibitors Reduce Cell Death in Etoposide-Treated Primary Cortical Neurons. In parallel studies, we examined the effects of the DNA-damaging and proapoptotic agent etoposide on cell cycle induction and apoptosis in rat primary cortical neurons. We treated cultures with etoposide (50 M) to induce DNA damage and cell death and tested the effect of the CDK cell cycle inhibitors flavopiridol, roscovitine, or olomoucine on neuronal survival. All these compounds are selective CDK inhibitors, although they have somewhat different affinity and selectivity for specific CDKs and inhibit the G 1 -S and G 2 -M transition phases of the cell cycle (37, 38). Cell viability [lactate dehydrogenase (LDH) release] and degree of apoptotic cell death (cells with Hoescht-positive nuclei) were evaluated 24 h after treatment. In addition, protein levels for cyclin D1, PCNA, and p27 were measured by immunoblotting. Etoposide significantly reduced cell viability as reflected by LDH release (250% increase) (Fig. 2a) and significantly induced apoptotic nuclear condensation resulting in 225% increase in cells with apoptotic nuclei (Hoechst-positive) (Fig. 2b). Flavopiridol at 1-, 10-, or 100- M concentrations significantly reduced LDH release (from 250% to 120%) as well as the number of apoptotic cells (225% to 135%, Fig. 2 a and b). Administration of roscovitine or olomoucine in parallel experiments also reduced LDH release and neuronal apoptosis after etoposide treatment. Roscovitine or olomoucine caused 22% and 51% reduction of etoposide-induced LDH release, respectively. Immunoblotting showed increased expression of cyclin D1 and PCNA after etoposide, which was inhibited when flavopiridol was added 1 hour before etoposide administration (Fig. 2c). In contrast, expression of the endogenous CDK inhibitor p27 was strongly inhibited by etoposide and was reversed by flavopiridol treatment (Fig. 2c). Active caspase 3 was strongly induced by etoposide but reversed after flavopiridol treatment (Fig. 2c). This result suggests that inhibition of aberrant cell cycle progression plays a role in neuronal survival after DNA damage in cortical neurons. CDK Inhibitors Reduce Proliferation of Primary Cortical Astrocytes. We also examined the effects of flavopiridol or roscovitine on astrocyte proliferation in vitro. Rat brain astrocytes were dissected and put in culture according to standard procedures as described (35). Proliferation was induced with 24 h of serum stimulation (10% FBS). Drugs were added to either serum-treated or nontreated (baseline samples) cells at different concentrations: flavopiridol at 100 nm, 1 M, and 10 M or roscovitine at 1 M, 10 M, and 100 M for 48 h. Cell viability assay (Cell Titer 96 Aqueous One Solution Cell Proliferation Assay, Promega) was used to measure modulation of cell proliferation after serum alone versus serum plus flavopiridol treatment. Flavopiridol or roscovitine reduced cell proliferation in a concentration-dependent manner (Fig. 2d), although, flavopiridol was far more effective. Cell numbers after 10 M flavopiridol were comparable with nonstimulated cells, showing that the drug entirely blocked proliferation of astrocytes (Fig. 2d). Flavopiridol treatment also completely attenuated cyclin D1 and PCNA protein expression after FBS, as shown by immunoblotting (Fig. 2e). In parallel experiments, cells were collected for cell cycle profile analysis by using FACS cell sorting. Importantly, S phase was increased by 224% after serum stimulation, compared with baseline, and restored to baseline levels after flavopiridol treatment (10 M) (Fig. 2f). No evidence of cell death was found cgi doi pnas Di Giovanni et al.
3 Fig. 1. Cell cycle and DNA damage-related mrna and protein changes after TBI. (a) Shown is a dendrogram (gene tree) obtained nucleating altered transcripts between sham and injured brains. Bar graph (Right) shows the color code for gene expression levels from low (blue) to high (red). These transcripts are up-regulated between 4 and 72 h after TBI (gene names in yellow indicate a Welch t test P value 0.05 between sham and injured at one corresponding time point). (b) Table shows genename, accessionnumber, andquantitation (foldchanges) ofmrnachangesbyaffymetrixforthetranscriptsrepresentedinthedendrogram. Genes withasterisks indicate a Welch t test P value 0.05 between sham and injured at the corresponding time point. (c) RT-PCR confirms expression of mrnas for GADD45, PCNA, c-myc, and p27 (ribosomal protein L-19 was used as control). (d) Immunoblots show increased GADD45 and PCNA protein levels in injured (I), versus sham (S) brains at 24 h in two parallel experiments. -Actin is a loading control. (e) Immunoblotting at 72 h shows induction of cyclin D1 and inhibition of p27 protein expression after TBI in injured (I) versus sham (S) brains; flavopiridol (F) rescues p27 expression and inhibits cyclin D1. -Actin is a loading control. NEUROSCIENCE in astrocytes after flavopiridol treatment (data not shown), as measured by Hoechst staining. Flavopiridol Reduces Neuronal Cell Death, Microglial Activation, Astroglial Proliferation, and Scar Formation After TBI. To evaluate the effect of flavopiridol in vivo on neuronal death and glial proliferation through modulation of cell cycle, we performed immunoblotting and immunocytochemistry experiments after TBI in rats, comparing brains from animals treated by intraventricular delivery of flavopiridol or vehicle. Immunoblotting comparing cortex from shams, vehicle-treated rats, and flavopiridol-treated rats at 72 h posttrauma showed that cyclin D1 expression was induced after TBI and strongly inhibited by flavopiridol, whereas p27 expression was inhibited after injury and normalized after treatment (Fig. 1e). Immunohistochemistry was performed in sham, vehicle, and flavopiridol-treated rats at 24 and 72 h. Double- and triple-labeling experiments were done with either neuronal-specific marker NeuN, astrocyte marker GFAP, or activated microglia marker OX-42, together with cyclin D1 and or activated caspase 3. Trauma increased expression of cyclin D1 in neurons, microglia, and astrocytes at 24 and 72 h. Cell counting was performed in both cortex and hippocampus at 72 h, and % of neurons showed expression of cyclin D1 in cortex around the injury site compared with % in the contralateral cortex of vehicletreated animals. Cyclin D1-positive neurons were reduced to % after flavopiridol in the injury region area (Fig. 3a); % of neurons expressing cyclin D1 after injury were also positive for active caspase 3, compared with % in the contralateral cortex, and to % after flavopiridol (Fig. 3b). In the ipsilateral hippocampus, % of neurons were cyclin D1-positive compared with % on the contralateral side in vehicle-treated animals and % in flavopiridol-treated animals ipsilaterally (Fig. 6a, which is published as supporting information on the PNAS web site). Moreover, % cyclin D1-positive neurons after injury were also positive for caspase 3, whereas only rare active caspase 3 and cyclin D1-positive cells were detected in the contralateral side, and after flavopiridol (Fig. 6b). Astrocyte proliferation was observed in the cortex around the injury site after trauma as an increase in number of GFAP-positive cells. Astrocytes positive for cyclin D1 and PCNA were also increased at both 24 and 72 h. GFAP-positive cells increased by % in the injured cortex compared with the controlateral region. We found that % GFAP-positive cells around the injury site were also positive for cyclin D1 (Fig. 4a). Flavopiridol treatment limited the increase of GFAP-positive cells around the injury to only % compared with the contralateral cortex (Fig. 4a). Cyclin D1 was present only in % GFAP-positive cells around the injury site after flavopiridol treatment (Fig. 4a). A % increase in GFAP-positive cells occurred in the ipsilateral hippocampus compared with the contralateral side in vehicle- Di Giovanni et al. PNAS June 7, 2005 vol. 102 no
4 Fig. 2. Flavopiridol promotes neuronal survival after DNA damage and inhibits astrocyte proliferation by blocking cell cycle proteins and cell cycle progression. (a and b) Flavopiridol treatment protects cells from death induced by etoposide (LDH release) (a) and number of Hoechst-positive cells (b) in primary cortical neurons at 24 h. (c) Immunoblotting shows expression of cell cycle proteins and caspase 3 after etoposide treatment, and etoposide plus flavopiridol treatment from rat cortical neuronal cells after treatment with etoposide (lane E) and after etoposide plus flavopiridol (lane E F) at 24 h. (d) Flavopiridol blocks proliferation of cultured rat astrocytes. Shown are data from MTT cell viability assay in astrocytes after serum stimulation and treatment with flavopiridol. Values on y axis are expressed in OD, reflecting number of viable cells. (e) Flavopiridol completely suppresses cyclin D1 and PCNA protein expression in proliferating astrocytes. Immunoblotting at 48 h after serum stimulation (lane FBS) shows induction of cyclin D1 and PCNA compared with control resting astrocytes (lane C). Flavopiridol in duplicate experiments, administered 1 h before FBS completely suppresses cyclin D1 and PCNA protein expression (lanes FBS F). (f) Flavopiridol reduces S phase in proliferating astrocytes to basal levels (FACS). treated animals. We found that % GFAP-positive cells were also cyclin D1-positive, whereas, after flavopiridol, there was only a % increase in GFAP-positive cells in the hippocampus, and only 2 0.2% were also cyclin D1-positive (Fig. 4b). There was a strong increase in immunoreactivity for active microglia marker OX-42 in the cortex around the injury site after injury, whereas no active microglia were detected in the controlateral cortex: % of OX-42-positive cells were also cyclin D1- positive (Fig. 4c) and PCNA-positive (data not shown). Flavopiridol treatment reduced the number of activated microglia to % compared with the vehicle-treated animals, and only rare cyclin D1-positive cells were found (Fig. 4c). At 28 days post-trauma, the injured cortex was compared between vehicle and flavopiridol-treated animals. Brains were immunostained with GFAP antibody for astroglia and TOPRO nuclear staining. Less tissue loss was evident at the injury site in the flavopiridol-treated animals versus vehicle (Fig. 4d), with the rim of GFAP-positive cells around the central area of tissue loss markedly reduced. Given the near absence of a defined lesion in the flavopiridol-treated animals, in contrast to controls, quantitative com- Fig. 3. Immunofluorescence shows the expression of cyclin D1 and active caspase 3 in cortical neurons after TBI, and effects of flavopiridol treatment. (a) Double immunofluorescence in coronal sections of the brain cortex around the injury site shows staining for cyclin D1 in vehicle, and flavopiridol-treated animal after TBI, and for the neuronal marker NeuN. Cyclin D1 expression is induced in cortical neurons after TBI and strongly reduced after flavopiridol compared with vehicle (arrows). (Original magnification: 125.) Bar graphs show quantitation of cortical neurons expressing cyclin D1 in ipsilateral and contralateral cortex in vehicle-treated rats, compared with flavopiridol (ipsilateral) (**, P 0.01). (b) Double immunofluorescence in coronal sections of the brain cortex around the injury site shows staining for cyclin D1 in vehicle, and flavopiridol-treated animal after TBI, and for active caspase 3. Flavopiridol strongly reduces cyclin D1-positive and active caspase 3-positive neurons (arrows). (Original magnification: 125.) Bar graphs show quantitation of cortical neurons coexpressing cyclin D1 and cleaved caspase 3 in ipsilateral and contralateral cortex in vehicle-treated rats, compared with flavopiridol (ipsilateral) (**, P 0.01) cgi doi pnas Di Giovanni et al.
5 NEUROSCIENCE Fig. 4. Immunofluorescence in glial cells after TBI and flavopiridol treatment. (a) Double immunofluorescence in coronal sections of brain cortex around the injury site shows staining for cyclin D1 and for astrocyte marker GFAP in vehicle, and flavopiridol-treated animals after TBI. Strong reduction of cyclin D1-positive and GFAP-positive cells is present after flavopiridol compared with vehicle (arrows). (Original magnification: 125.) Bar graphs show quantitation of these data (**, P 0.01). (b) Double immunofluorescence in coronal sections of hippocampus (CA1 and CA2) on the injury site shows staining for cyclin D1 and GFAP in vehicle, and flavopiridol-treated animal after TBI. Strong reduction of cyclin D1-positive and GFAP-positive cells is present after flavopiridol compared with vehicle (arrows). (Original magnification: 125.) Bar graphs show quantitation of these data (*, P 0.05; **, P 0.01). (c) Double immunofluorescence in coronal sections of brain cortex around the injury site shows staining for cyclin D1 and for activated microglia marker OX-42 in vehicle, and flavopiridol-treated animals after TBI. Just sporadic GFAP-positive cells are present after flavopiridol (arrows). (Original magnification: 125.) (d) Immunostaining for GFAP and nuclear marker (TOPRO) in ipsilateral cortex after TBI, comparing vehicle and flavopiridol-treated rats at 28 days posttrauma. Flavopiridol (250 M) limits the injury-induced reactive gliosis and tissue loss. (Original magnification: 125.) parisons of the scar volume per se was not feasible. However, lesion differences between treated and control animals, as observed by histology, paralleled reductions in lesion volume observed by MRI. Fig. 5. Flavopiridol significantly reduces lesion volume 21 days after TBI in rats. (a) Bar graph shows significant reduction of lesion volume 21 days after TBI (30 min after the injury, at 250 mol i.c.v.; n 7; lesion volumes: mean SEM); (**, P 0.01 vs. FP plus vehicle). (b) Representative T 2 -weighted MRI of vehicle and flavopiridol-treated rats shows marked reduction of lesion volume. (c) Flavopiridol improves cognitive performance as measured by the Morris water maze test (***, P compared with sham control animals). (d) Flavopiridol restores motor function close to control levels. Results are shown as daily mean SEM (**, P 0.01 and ***, P vs. sham controls). Flavopiridol Reduces Lesion Volume and Favors Functional Recovery in Vivo After TBI. To further address whether inhibition of cell cyclerelated proteins reduces the lesion volume after TBI, we administered 250 M flavopiridol intracerebroventricularly (i.c.v.) 30 min after injury, and performed T2-weighted MRI 21 days after trauma. A marked and significant reduction of brain lesion volume was found in flavopiridol-treated injured animals as compared with vehicle controls (Fig. 5 a and b). We also examined the effects of flavopiridol administration on trauma-induced cognitive deficits, measured by Morris water maze test; flavopiridol treatment prevented the injury-induced cognitive deficit (Fig. 5c). Moreover, flavopiridol-treated animals recovered motor function to levels similar to those of uninjured controls (Fig. 5d), in contrast to vehicle-treated animals that remained substantially impaired. Di Giovanni et al. PNAS June 7, 2005 vol. 102 no
6 Discussion Our data show that activation of cell cycle proteins after TBI is associated with cell death and caspase activation in neurons, but with proliferation of astrocytes and microglia. Moreover, cell cycle inhibition by flavopiridol treatment reduces neuronal cell death, as well as astroglial and microglial proliferation. Importantly, these changes were paralleled by a remarkable reduction in lesion volume and by nearly complete functional recovery. These data are consistent with the hypothesis that activation of cell cycle proteins in postmitotic cells, such as neurons, triggers an aberrant cell cycle reentry mechanism that leads to cell death (12 14). In vivo studies of cortical or spinal cord neurons after ischemia or excitotoxic-mediated DNA damage have shown the occurrence of apoptotic cell death associated with cyclin D1-cdk4, cyclin G, PCNA, or Rb E2F protein and mrna overexpression (21 25). Inhibition of neuronal death, and improvement of functional recovery with flavopiridol treatment has been reported after brain ischemia in rats, although effects on glial and microglial cells were not addressed (39, 40). We have also recently shown that similar changes in cell cycle genes occur 24 h after experimental spinal cord injury and were expressed in neurons showing signs of DNA damage and apoptotic cell death (33). Thus, expression of cell cycle proteins may reflect DNA damage, attempted repair, and subsequent apoptosis of injured neurons under diverse experimental conditions. Cell cycle inhibitors, including flavopiridol, have been shown to protect injured primary neurons from cell death by blocking proteins involved in the G 1 S phase of cell cycle (41, 42). We induced DNA damage and examined cell cycle induction in cultured primary cortical neurons. Administration of etoposide caused caspase-associated neuronal apoptosis at 24 h, accompanied by induction of cyclin D1 and PCNA and the reduction of p27. Moreover, cell cycle inhibition significantly reduced cell death, inhibited protein expression of cyclin D1 and PCNA, and enhanced p27 expression. Cell cycle inhibitors also effectively blocked glial proliferation in vitro. Taken together, these data suggest that cell cycle inhibition after DNA damage and aberrant cell cycle reentry reduces caspase-mediated neuronal apoptosis and may inhibit proliferation of mitotic cells such as astroglia or microglia. After TBI, flavopiridol treatment reduced the expression of cell cycle proteins in neurons and glia, decreased neuronal apoptosis and caspase expression in ipsilateral cortex and hippocampus, and limited microglial and astroglial proliferation after injury. These changes were associated with remarkable improvement in tissue preservation and behavioral outcome. This striking degree of neuroprotection likely reflects the multifactorial actions of this drug class: attenuating posttraumatic neuronal cell loss; reducing the induction of reactive microglia with the likely related decrease of microglial-associated inflammatory factors; and limiting astroglial proliferation and the associated glial scar, with potential reduction of glial-induced inhibitors of regeneration plasticity. It should be emphasized that cell death was not induced in nonproliferating glial cells by flavopiridol, suggesting that cell cycle inhibition does not affect physiological levels of astroglia, which may be important for support and production of trophic factors in the CNS. Moreover, it is likely that early inhibition of proliferating reactive astrocytes and microglia would impair production and later accumulation of molecules (such as proteoglycans) involved in glial scar formation. Flavopiridol has been tested in phase I and II clinical trials as a potential antineoplastic agent, including leukemias lymphomas, non-small-cell lung cancer, non-hodgkin lymphoma, and prostate, colon, gastric, and kidney carcinomas (37, 38). Although it has not proved effective as a clinical anti-cancer agent to date, it has largely proved to be safe at doses needed to block induction of cell cycle proteins in animal models. Possible use of cell cycle inhibitors for treatment of stroke or trauma would only require acute or subacute administration, thereby further reducing potential toxicity. We conclude that use of cell cycle inhibitors may provide an effective therapeutic target for the treatment of CNS trauma because of their multimodal actions, which include inhibition of neuronal cell death, the posttraumatic inflammatory response, and glial scar formation. We thank Idalia Cruz, Elvira Dabaghyan, Lioudmila Zoubak, and Jeanette Beers for technical assistance. This work was supported by National Institutes of Health (NIH) Grant NS and Contract NIH-NINDS-01 (NS ) (to A.I.F.) and NIH Grant HD Raghupathi, R. (2004) Brain Pathol. 14, McGraw, J., Hiebert, G. W. & Steeves, J. D. (2001) J. Neurosci. Res. 63, Yakovlev, A. G. & Faden, A. I. (2001) Mol. Neurobiol. 24, Liou, A. K., Clark, R. S., Henshall, D. C., Yin, X. M. & Chen, J. T. (2003) Prog. Neurobiol. 69, Faden, A. I. (2002) Curr. Opin. Neurol. 15, Lotocki, G., Alonso, O. F., Frydel, B., Dietrich, W. D. & Keane, R. W. (2003) J. Cereb. Blood Flow Metab. 23, Frantseva, M., Perez-Velazquez, J. L., Tonkikh, A., Adamchik, Y. & Carlen, P. L. (2002) Prog. Brain Res. 137, Ray, S. K. & Banik, N. L. (2003) Curr. Drug Targets CNS Neurol. Disord. 2, Knoblach, S. M., Alroy, D. A., Nikolaeva, M., Cernak, I, Stoica, B. A. & Faden, A. I. (2004) J. Cereb. Blood Flow Metab. 24, Kuan, C. Y., Whitmarsh, A. J., Yang, D. D., Liao, G., Schloemer A. J., Dong, C., Bao, J., Banasiak, K. J., Haddad, G. G., Flavell, R. A., Davis, R. J. & Rakic, P. (2003) Proc. Natl. Acad. Sci. USA 100, Hu, B., Liu, C., Bramlett, H., Sick, T. J., Alonso, O. F., Chen, S & Dietrich, W. D. (2004) J. Cereb. Blood Flow Metab. 24, Becker, E. B. & Bonni, A. (2004) Prog. Neurobiol. 72, Copani, A., Uberti, D., Sortino, M. A., Bruno, V., Nicoletti, F. & Memo, M. (2001) Trends Neurosci. 24, Liu, D. X. & Greene, L. A. (2001) Cell Tissue Res. 305, Freeman, R. S., Estus, S. & Johnson, E. M. Jr. (1994) Neuron 12, Padmanabhan, J., Park, D. S., Greene, L. A. & Shelanski, M. L. (1999) J. Neurosci. 19, Kranenburg, O., van der Eb, A. J. & Zantema, A. (1996) EMBO J. 15, Boutillier, A. L., Trinh, E. & Loeffler, J. P. (2000) Oncogene 19, Park, D. S., Morris, E. J., Bremner, R., Keramaris, E., Padmanabhan, J., Rosenbaum, M., Shelanski, M. L., Geller, H. M & Greene L. A. (2000) J. Neurosci. 20, Herrup, K., Neve, R., Ackerman, S. L. & Copani, A. (2004) J. Neurosci. 20, Van Lookeren Campagne, M. & Gill, R. (1998) Neuroscience 84, Sakurai, M., Hayashi, T., Abe, K., Itoyama, Y., Tabayashi, K. & Rosenblum, W. I. (2000) Stroke 31, Ino, H. & Chiba, T. (2001) J. Neurosci. 21, Xiang, Z., Ho, L., Valdellon, J., Borchelt, D., Kelley, K., Spielman, L., Aisen, P. S. & Pasinetti, G. M. (2002) Neurobiol. Aging 23, Nguyen, M. D., Boudreau, M., Kriz, J., Couillard-Despres, S., Kaplan, D. R. & Julien, J. P. (2003) J. Neurosci. 23, Kato, H., Takahashi, A. & Itoyama, Y. (2003) Brain Res. Bull. 60, Koguchi, K., Nakatsuji, Y., Nakayama, K. & Sakoda, S. (2002) Glia 37, Fawcett, J. W. (1997) Cell Tissue Res. 290, McMillian, M. K., Thai, L., Hong, J. S., O Callaghan, J. P. & Pennypacker, K. R. (1994) Trends Neurosci. 17, Nieto-Sampedro, M. (1999) Adv. Exp. Med. Biol. 468, Ridet, J. L., Malhotra, S. K., Privat, A. & Gage, F. H. (1997) Trends Neurosci. 20, Natale, J. E., Ahmed, F., Cernak, I., Stoica, B. & Faden, A. I. (2003) J. Neurotrauma 20, Di Giovanni, S., Knoblach, S. M., Brandoli, C., Aden, S. A., Hoffman, E. P. & Faden, A. I. (2003) Ann. Neurol. 53, Di Giovanni, S., Molon, A., Broccolini, A., Melcon, G., Mirabella, M., Hoffman, E. P. & Servidei, S. (2004) Ann. Neurol. 55, Schinelli, S., Zanassi, P., Paolillo, M., Wang, H., Feliciello, A. & Gallo, V. (2001) J. Neurosci. 21, Faden, A. I., Knoblach, S. M., Cernak, I., Fan, L., Vink, R., Araldi, G. L., Fricke, S. T., Roth, B. L. & Kozikowski, A. P. N. (2003) J. Cereb. Blood Flow Metab. 23, Senderowicz, A. M. (2003) Oncogene 22, Swanton, C. (2004) Lancet Oncol. 5, Osuga, H., Osuga, S., Wang, F., Fetni, R., Hogan, M. J., Slack, R. S., Hakim, A. M., Ikeda, J. E. & Park, D. S. (2000) Proc. Natl. Acad. Sci. USA 97, Wang, F., Corbett, D., Osuga, H., Osuga, S., Ikeda, J. E., Slack, R. S., Hogan, M. J., Hakim, A. M. & Park, D. S. (2002) J. Cereb. Blood Flow Metab. 22, Bartek, J. & Lukas, J. (2001) FEBS Lett. 490, Kruman, I. I., Wersto, R. P., Cardozo-Pelaez, F., Smilenov, L., Chan, S. L., Chrest, F. J., Emokpae, R., Jr., Gorospe, M. & Mattson, M. P. (2004) Neuron 41, cgi doi pnas Di Giovanni et al.
Neurotrophic factors and Their receptors Huang Shu-Hong Institute of neurobiology 1 For decades, scientists believed that brain cells of the central nervous system could not regrow following damage due
Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1
13-14/11/2006, Istituto Superiore di Sanità Rome, Italy Frontiers in Imaging Science: High Performance Nuclear Medicine Imagers for Vascular Disease Imaging (Brain and Heart) Stem cells for brain cures
CHAPTER- 6 Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats 1. Introduction Neurodegenerative disorders, such as AD are often characterized by the degeneration of the
Diffusion Kurtosis a Sensitive Marker For Traumatic Brain Injury Jiachen Zhuo, Su Xu, Julie Hazelton, Roger Mullins, Jonathan Simon, Gary Fiskum, Rao Gullapalli Dept. of Radiology, University of Maryland
CAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological
Stroke & Alzheimer s Disease: An Inflammatory Duo Stroke and Dementia One in 3 will experience a stroke, dementia or both 64% of persons with a stroke have some degree of cognitive impairment and up to
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC
[ID]FIGS1[/ID] [ID]FIGS2[/ID] [ID]FIGS3[/ID] [ID]FIGS4[/ID] [ID]FIGS5[/ID] [ID]FIGS6[/ID] [ID]TBLS1[/ID] [ID]TBLS2[/ID] SUPPLEMENTAL MATERIAL Wolf et al., http://www.jem.org/cgi/content/full/jem.20101470/dc1
Psychology 3625 Cellular and Molecular Neuroscience Dr Darren Hannesson Lecture 6 Cells of the nervous system Neurons Glia Other cell types Blood-brain barrier Types of nervous system cells Neurons The
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
Bottlenecks in Clinical Source Material Acquisition Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA firstname.lastname@example.org Biopreservation What s the issue? Biopreservation considerations
1 Supplemental data Supplemental Fig. S1. The schematic diagrams of the expression constructs used in this study. Supplemental Fig. S2. Ingenuity Pathway Analysis (IPA) of the 56 putative caspase substrates
THE SPINAL CORD AND THE INFLUENCE OF ITS DAMAGE ON THE HUMAN BODY THE SPINAL CORD. A part of the Central Nervous System The nervous system is a vast network of cells, which carry information in the form
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
LIST OF FIGURES Figure 1: Diagrammatic representation of electromagnetic wave. Figure 2: A representation of the electromagnetic spectrum. Figure 3: Picture depicting the internal circuit of mobile phone
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
Brain Research Center Medical University of Vienna Molecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD) IMMUNOLOGY OF MULTIPLE SCLEROSIS Noseworthy et al 2000 NEJM Immunomodulatory Treatment
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
Translating DNA repair pathways into therapeutic targets: beyond the BRCA1/2 and PARP inhibitor saga Jorge S Reis-Filho, MD PhD FRCPath Summary How do PARP inhibitors work? Synthetic lethality Potential
Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral
Neurobiology of Depression in Relation to ECT PJ Cowen Department of Psychiatry, University of Oxford Causes of Depression Genetic Childhood experience Life Events (particularly losses) Life Difficulties
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
No Disclosures Gregory A. Brent, MD Departments of Medicine and Physiology David Geffen School of Medicine at UCLA VA Greater Los Angeles Healthcare System Learning Objectives Describe the pathways that
Influence of GSM and UMTS on the Blood Brain Barrier in vitro additional results Intl. Workshop on long term effects, München, 11.-12. Okt. 2007 Dr. rer. nat. Helmut Franke Klinik und Poliklinik für Neurologie
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
ONLINE SUPPLEMENTAL MATERIAL Allele-Specific Expression of Angiotensinogen in Human Subcutaneous Adipose Tissue Sungmi Park 1, Ko-Ting Lu 1, Xuebo Liu 1, Tapan K. Chatterjee 2, Steven M. Rudich 3, Neal
STROKE CARE NOW NETWORK CONFERENCE MAY 22, 2014 Rehabilitation Innovations in Post- Stroke Recovery Madhav Bhat, MD Fort Wayne Neurological Center DISCLOSURE Paid speaker for TEVA Neuroscience Program.
Promising Treatments for SCI: What s on The Horizon Shawn Song, MD SCI Fellow University of Washington/VA Puget Sound Healthcare System SCI: A Devastating Injury Epidemiology: Incidence of ~12,000 patients/year.
The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke a,b* b,c a a b b b b a b a b c 430 Wang et al. Acta Med. Okayama Vol.
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
STEM CELL FACTS The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. WHAT ARE STEM CELLS? Stem cells are the foundation cells for
Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)
RUTGERS W. M. KECK CENTER FOR COLLABORATIVE NEUROSCIENCE 604 Allison Road, 0251, Piscataway, NJ 08854-8082 USA Dept. of Cell Biology and Neuroscience (732) 445-1781, (732) 445-6576, Fax: (732) 445-2063
Supplemental Data 1 Online supplemental information Statistical analysis Cell viability assays were represented as mean ± S.E. (n=3). Comparisons between the groups were performed using repeated measures
BACKROUNDER: Newborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function Introduction WITH ONGOING DEVELOPMENTS IN RESEARCH, it is estimated that 1 in every 3 people may benefit
Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
Stem Cells is the main material for building and regeneration of the body Stem cells are not differentiated and can transform to any cell of organism Stem cells are capable of indefinite renewal through
Motor dysfunction 2: Spinal cord injury and subcortical motor disorders ANATOMY REVIEW: Basal Ganglia A group of subcortical nuclei caudate, putamen, globus pallidus Caudate & Putamen = Neostriatum caudate
Identification of the androgen receptor aggregates that cause spinal-bulbar muscular atrophy Dr Xavier Salvatella Giralt CSIC Consell Superior d'investigacions Científiques Institut Recerca Biomèdica de
Essentials of Real Time PCR About Real-Time PCR Assays Real-time Polymerase Chain Reaction (PCR) is the ability to monitor the progress of the PCR as it occurs (i.e., in real time). Data is therefore collected
Head of College Scholars List Scheme Summer Studentship Report Form This report should be completed by the student with his/her project supervisor. It should summarise the work undertaken during the project
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
Supplemental Material Goldoni et al., http://www.jcb.org/cgi/content/full/jcb.200901129/dc1 THE JOURNAL OF CELL BIOLOGY Figure S1. Specific high affinity interaction between decorin and Met-Fc. (A) Ligand-binding
Number of Students Part 1: Don t get testy! Introduction: Ms. Smith, the high school English Language Arts teacher, made a graph of the exam scores from a recent test she gave her 27 students as she always
neuroscience Promoting Remyelination and Preventing Demyelination New Research Goals in Finding a Therapy for Multiple Sclerosis Priya Rajgopal 11 24 Recent Multiple Sclerosis (MS) research has made it
Special report Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006 Gene And Protein The gene that causes the mutation is CCND1 and the protein NP_444284 The mutation deals with the cell
UNIVERSITA DEGLI STUDI DI PADOVA Dipartimento di Anatomia e Fisiologia Umana Department of Human Anatomy and Physiology High frequency low intensity current effects: bio-stimulation and cellular regeneration
Introduction To Real Time Quantitative PCR (qpcr) SABiosciences, A QIAGEN Company www.sabiosciences.com The Seminar Topics The advantages of qpcr versus conventional PCR Work flow & applications Factors
Stem Cell Quick Guide: Stem Cell Basics What is a Stem Cell? Stem cells are the starting point from which the rest of the body grows. The adult human body is made up of hundreds of millions of different
AAGPs TM Anti-Aging Glyco Peptides Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule 1 Acknowledgements This presentation was prepared by Dr. Samer Hussein
Supporting Information Kondo et al. 1.173/pnas.787415 SI Methods Conventional and Quantitative RT-PCR. Total RNA was extracted from cultured ES cells or ES-derived cells using the RNeasy Minikit (Qiagen).
Fighting the Battles: Conducting a Clinical Assay 6 Vocabulary: In Vitro: studies in biology that are conducted using components of an organism that have been isolated from their usual biological surroundings
Calendar Year 2013 Centers for Medicare and Medicaid Services (CMS) New and Reconsidered Clinical Laboratory Fee Schedule (CLFS) Test Codes And Final Payment Determinations Reconsideration Code 86386 Reconsideration
Cell Division Mitosis and the Cell Cycle A Chromosome and Sister Chromatids Key Points About Chromosome Structure A chromosome consists of DNA that is wrapped around proteins (histones) and condensed Each
Cell Viability Assays: Microtitration (MTT) Viability Test Live/Dead Fluorescence Assay Proliferation Assay: Anti-PCNA Staining Spring 2008 1 Objectives To determine the viability of cells under different
Investigating the role of a Cryptosporidium parum apyrase in infection David Riccardi and Patricio Manque Abstract This project attempted to characterize the function of a Cryptosporidium parvum apyrase
Correlation of microarray and quantitative real-time PCR results Elisa Wurmbach Mount Sinai School of Medicine New York Microarray techniques Oligo-array: Affymetrix, Codelink, spotted oligo-arrays (60-70mers)
Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation Steffen Gay Arthritis linked to cardiovascular disease CV Death Osteoarthritis CHF Rheumatoid
Kinexus Bioinformatics Corporation is seeking to map and monitor the molecular communications networks of living cells for biomedical research into the diagnosis, prognosis and treatment of human diseases.
Animal Cell Culture Third Edition A Practical Approach Edited by John R. W. Masters 3rd Floor Research Laboratories, University College London OXJORD VNIVVRSITY 1'RVSS Contents List of protocols page xiii
Long-Term Effects of Drug Addiction Part 1: Addiction is a chronic disease Drug addiction is considered a chronic brain disease because drugs cause long-lasting changes in brain structure and function.
HUNTINGTON S DISEASE MULTIDISCIPLINARY CLINIC HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE From gene to treatments The gene that causes Huntington s disease (HD) was discovered in 1993. Since then, enormous
Advanced MRI methods in diagnostics of spinal cord pathology Stanisław Kwieciński Department of Magnetic Resonance MR IMAGING LAB MRI /MRS IN BIOMEDICAL RESEARCH ON HUMANS AND ANIMAL MODELS IN VIVO Equipment:
Application Note No. 2 / July 2012 Quantitative Assessment of Cell Quality, Viability and Proliferation System Quantitative Assessment of Cell Quality, Viability and Proliferation Introduction In vitro
High throughput screening:layout 1 26/3/09 13:32 Page 25 High throughput screening, high content screening, primary and stem cells new techniques now converging Over the past decade, the use of cell-based
We have made the following changes to the Critical Illness events covered under our group critical illness policy. March 2015 Because everyone needs a back-up plan 7 New critical illness events added to
The RNA strategy RNA as a tool and target in human disease diagnosis and therapy. The Laboratory of RNA Biology and Biotechnology at the Centre for Integrative Biology (CIBIO) of the University of Trento,
Focus on CNS Drug Development Treating secondary progressive multiple sclerosis Simon Wilkinson, CEO Forward Looking Statements 2 This Presentation (and any financial information that may be provided by
Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell
http://abcnews.go.com/politics/video/obama-says-brain-initiative-will-be-transformative-18861944 What are the nervous system s functions? The nervous system organizes and controls an individual s appropriate
Growth of Animal Cells in Culture The ability to study cells depends largely on how readily they can be grown and manipulated in the laboratory. Although the process is technically far more difficult than
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies 1 Biochemistry Journal August 1, 2007 405, pp. 559 568 Joseph Friedman, Sarah Kraus, Yirmi Hauptman, Yoni Schiff
技 術 專 員 費 軫 尹 20100803 Overview of presentation Basic Biology of RNA interference Application of sirna for gene function? How to study mirna? How to deliver sirna and mirna? New prospects on RNAi research
Paul A. Lapchak, PhD Director of Translational Research Director of the Stroke Screening Facility Department of Neurology & Neurosurgery STROKE DRUG DE-RISKING & DEVELOPMENT FOR INDUSTRY Barbara and Marvin
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex
Nyt indenfor MS ved MR Update: MRI in Multiple sclerosis Hartwig Roman Siebner Danish Research Centre for Magnetic Resonance (DRCMR) Copenhagen University Hospital Hvidovre Dansk Radiologisk Selskabs 10.
Laser Phototherapy: New Modality for Nerve Cell Tissue Engineering Technology, Cell Therapy and Nerve Repair S. Rochkind Division of Peripheral Nerve Reconstruction, Department of Neurosurgery, Tel viv
In Vivo and In Vitro Screening for Thyroid Hormone Disruptors Kevin M. Crofton National lhealth and Environmental Research Laboratory California Environmental Protection Agency Human Health Hazard Indicators